Results 11 to 20 of about 352 (104)

Romiplostim for thrombocytopenia following allogeneic stem cell transplantation: A case series

Hematology/Oncology and Stem Cell Therapy, 2020
Thrombocytopenia is a relatively common complication following allogeneic hematopoietic stem cell transplantation and is associated with increased bleeding, transfusion requirements, chronic graft-versus-host disease, and all-cause mortality.
Guido Lancman, Alexander Coltoff, Amir Steinberg   +2 more
doaj   +1 more source

Romiplostim use for thrombocytopenia following allogeneic hematopoietic stem cell transplantation: a case series from a single center in Qatar

Hematology, 2023
Thrombocytopenia is a common and serious complication that can occur following hematopoietic stem cell transplantation (HSCT), and it contributes to increased morbidity and mortality.
Abdulrahman F. Al-Mashdali, Amaal Gulied, Mohammed M. Bakr, Mohamed A. Yassin   +3 more
doaj   +1 more source

Use of Romiplostim during pregnancy as a rescue therapy in primary immune thrombocytopenia: Literature review and case description

Platelets, 2020
Thrombocytopenia could appear during pregnancy, in up to 8–10% of the cases, where 3–5% is related to an autoimmune process so-called immune thrombocytopenia (ITP). We present a 34-year-old woman debuted at 13 weeks gestation, with a platelet count of 19 
Rodriguez Nuñez Rosa María, Rubio Lacambra Laura, Palomo Bravo Ángeles, Langenhorst Baniandres Laura   +3 more
doaj   +1 more source

Uso de romiplostim en trombocitopenia inmunitaria: experiencia en Cuenca (Ecuador)

Biomédica: revista del Instituto Nacional de Salud
Introducción. El consenso internacional y la guía del 2019 de la American Society of Hematology, establecieron a los análogos de la trombopoyetina como medicamentos de segunda línea para tratar la trombocitopenia inmunitaria primaria.
Héctor Chiang-Wong, Patricio González-Saldaña   +1 more
doaj   +1 more source

Use of romiplostim for antineoplastic therapy-induced thrombocytopenia in gynecologic and breast cancers

Gynecologic Oncology Reports
Objective: Romiplostim is used to treat chemotherapy-induced thrombocytopenia in a variety of tumor types; however, few studies have examined its use in breast and gynecologic cancers.
Sara Moufarrij, Roisin E. O'Cearbhaill, Qin Zhou, Alexia Iasonos, Simon Mantha, Jeffrey Zwicker, Cy R. Wilkins   +6 more
doaj   +1 more source

Is There a Role for Biweekly Romiplostim in the Management of Chronic Immune Thrombocytopenia (ITP)? A Report of Three Cases

Case Reports in Hematology, 2018
Romiplostim is a peptibody, which stimulates platelet production by a mechanism similar to that of endogenous thrombopoietin. It has an established indication as second-line therapy in patients with chronic immune thrombocytopenia (ITP).
Jasjit Kaur Rooprai, Karima Khamisa
doaj   +1 more source

Toxic interactions of Romiplostim and Rituximab in normal and thrombocytopenic Rats

Journal of Applied Veterinary Sciences, 2020
Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by immunologic destruction of normal platelets and insufficient production of platelets mediated by autoantibodies.
Saeed H., Sayed H.M., Ramadan A., Nahla S. Kotb   +3 more
doaj   +1 more source

Long-term treatment with romiplostim and treatment-free platelet responses in children with chronic immune thrombocytopenia

Haematologica, 2019
Children with immune thrombocytopenia for ≥6 months completing a romiplostim study received weekly subcutaneous romiplostim (1-10 μg/kg targeting platelet counts of 50-200×109/L) in this extension to examine romiplostim’s long-term safety and efficacy ...
Michael D. Tarantino, James B. Bussel, Victor S. Blanchette, Donald Beam, John Roy, Jenny Despotovic, Ashok Raj, Nancy Carpenter, Bhakti Mehta, Melissa Eisen   +9 more
doaj   +1 more source

Avatrombopag for persistent and chronic immune thrombocytopenia in children: A post hoc analysis of clinical characteristics of response from a phase 3b clinical trial

British Journal of Haematology, EarlyView.
Summary Avatrombopag treatment resulted in significantly higher platelet response rates in patients when compared with placebo in a phase 3b study of patients with paediatric immune thrombocytopenia (ITP) (NCT04516967). These post hoc analyses of the 12‐week core phase further assessed the efficacy of avatrombopag, considering the influence of baseline
Rachael F. Grace, Göksel Leblebisatan, Yesim Aydinok, Sule Unal, John Grainger, Amanda B. Grimes, Michele P. Lambert, Jessica Zhang, Brian D. Jamieson, Faizan Sattar, Scott Kolodny, Michael Vredenburg, on behalf of the AVA‐PED‐301 Study Group   +12 more
wiley   +1 more source

Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice

Hematology Reports, 2015
Thrombopoietin mimetics are new treatment options for patients with immune thrombocytopenia (ITP). Because of their mechanism of action, long-term administration was envisioned in order to maintain effective thrombopoiesis.
Monica Carpenedo, Silvia Cantoni, Veronica Coccini, Marilena Fedele, Enrica Morra, Enrico Maria Pogliani   +5 more
doaj   +1 more source